Updated Jul 16, 2026
Kung Winston has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $16K.
Winston Kung is the Chief Financial Officer at ArriVent BioPharma, Inc., a biopharmaceutical company focused on developing innovative therapies for patients with serious diseases. He has a background in finance and management within the biotech sector.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-13 | JANX | Janux Therapeutics, Inc. | A — Grant or award | 5.5K | $0.00 | |
| 2026-06-11 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | S — Open-market sale | 2.0K | $7.91 | $16K |
| 2026-05-21 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | A — Grant or award | 3.8K | $0.00 |
Winston Kung is the Chief Financial Officer at ArriVent BioPharma, Inc., a biopharmaceutical company focused on developing innovative therapies for patients with serious diseases. He has a background in finance and management within the biotech sector.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($16K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Kung Winston profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.